Navigation Links
American Oriental Bioengineering Comments on Recent Property Purchase
Date:1/9/2009

NEW YORK, Jan. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO" or "the Company"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today commented on its recent purchase of buildings and land in the Beijing Economic-Technological Development Area (BDA) for approximately $70.0 million.

Mr. Tony Liu, Chairman and Chief Executive Officer of AOBO, stated, "Our recent property purchase in the BDA is a long-term investment in AOBO which builds out our multi-functional headquarters and centralizes our management in Beijing, while deepening our presence in a very important development region focused on attracting leading pharmaceutical companies. Additionally, at a time when our significant cash position yields negative real returns, this fixed asset allocation does not constrain our financial flexibility, but rather, we believe, positions us to secure government support in various forms, such as R&D grants related to the PRC's stimulus plan as well as potential low-interest bank loans."

Liu continued, "While we have not always elaborated on our motivations at the time, due to economic, competitive and other reasons, we consistently and effectively have navigated China's complex economic and competitive landscape, and have created significant shareholder value in the process. We believe this property purchase is no departure from AOBO's proven past."

"Our goal remains consistent. We continue to focus on becoming a top-five pharmaceutical company in China and we are aggressively yet prudently pursuing organic and acquisition-led growth. We emphasize that China's challenging economic environment and the uncertainty created by the upcoming healthcare reform necessitates that we remain flexible, influential a
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tips from the journals of the American Society for Microbiology
2. Elsevier Introduces The American Journal of Medicine Blog
3. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
4. Transgenomic Receives Accreditation From College of American Pathologists
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
7. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
8. 100% Non-Incision Cosmetic Surgery, The 'Frame Thread Lift,' Debuts December 14, 2008 At American Academy Of Anti-Aging Medicine In Las Vegas
9. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
10. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
11. Growing Interest in DNA-Based Genetic Testing Among African American with Historic Election of President Elect Barack Obama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... 30, 2011 Current Ceo Rudi Pauwels ... , New Ceo   Appointment Strengthens ... Of Its   First Product In 2013 ... diagnostic (MDx) systems designed to drive personalized medicine and ...
... Nov. 30, 2011  DiaTech Life Sciences has announced the ... use of the Microculture Kinetic (MiCK) assay for ... chemotherapy is most effective for cancer patients. DiaTech has ... developed a model to assist pharmaceutical companies in validating ...
... today that Lex Van der Ploeg, PhD, has joined ... Ploeg brings to Rhythm more than 25 years of ... therapeutic areas. "Lex has considerable experience with ... are targeting with our ghrelin and melanocortin 4 receptor ...
Cached Biology Technology:Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 2Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 3Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 4DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2
(Date:5/11/2015)... -- Through a well-rounded UAS delegation representing private industry, government, and ... at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people from ... UAS ecosystem. "Our message is clear and ... Rich Knoll . "If you want to fly UAS, ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the most common type of lung cancer are notoriously ... to the cellular pathways that regulate responses to cisplatin ... 26th in the journal Cell Reports . The ... to predict how these patients will respond to chemotherapy, ...
... Hole Oceanographic Institution (WHOI) researchers have partnered with ... developed at WHOI: the Imaging FlowCytobot, an automated ... that uses light to provide wireless transmission of ... time. WHOI biologists Robert Olson and Heidi ...
... University of Leeds and the Chinese Academy of Sciences have ... next generation energy storage systems. Finding more effective and ... deal with the problem of peak demand on electricity grids. ... solar generation is also a pressing problem. People use ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 3WHOI scientists/engineers partner with companies to market revolutionary new instruments 4University of Leeds and Chinese Academy of Sciences join forces 2University of Leeds and Chinese Academy of Sciences join forces 3
Request Info...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: